In recent years, there have been significant advances in the treatment of hepatitis C. With 3 to 6 months of treatment, more than 90% of people infected with the hepatitis C virus can be cured. This has made people infected with the hepatitis B virus very hot-eyed. Some look forward to: “When will newer drugs become available to completely cure people infected with hepatitis B virus?” Some people are worried: “Most of the current antiviral drugs need to be taken for a long time, and the main problem they face is drug resistance. If the current antiviral drugs are resistant, will there be no more drugs to cure? Are there any new drugs left?” Scientists are not forgetting the 240 million people worldwide who are chronically infected with the hepatitis B virus. Efforts are underway to explore new safer and more effective drugs to treat chronic hepatitis B. Adefovir and tenofovir have the potential to cause kidney damage, and some patients have been shown to be particularly genetically susceptible to kidney damage with these two drugs. The chemical structure of tenofovir disoproxil fumarate (TDF), the currently marketed tenofovir ester, has been modified to become tenofovir alafenamide fumarate (tenofovir alafenamide fumarate (abbreviation: TAF). Although both drugs are precursors of tenofovir, the therapeutic dose of “TAF” is only 1/10 of “TDF”, which can achieve the same antiviral efficacy of “TDF”. TAF has the same antiviral efficacy as TDF at a dose of 1/10th of TDF, and greatly reduces the renal toxicity. Currently, tenofovir, known as “TAF”, is in clinical trials in China. Learning from the experience of direct antiviral drugs for hepatitis C, scientists have also begun to study the various aspects of hepatitis B virus replication in detail, trying to find a way to overcome the hepatitis B virus. Some people use a nucleic acid polymer to inhibit the release of hepatitis B surface antigen from hepatocytes infected with hepatitis B virus, so that the HBsAg in the body of the infected person is rapidly reduced, to achieve the purpose of removing the hepatitis B virus; others use a new technology called “RNA interference”; interference with the cccDNA of the hepatitis B virus to form a template, so that the virus The purpose of eradicating cccDNA is to keep transcriptional replication “silent”; others are working on a drug that can inhibit the assembly of the hepatitis B virus nucleocapsid so that the viral DNA cannot be assembled into complete viral particles after replication; ……. Preliminary results of these studies have been achieved so far. We, like all people infected with hepatitis B virus, are eagerly awaiting the success of these drug studies. The day when mankind will defeat the hepatitis B virus is no longer far away!